ALV-200 / Alveus Therapeutics - LARVOL DELTA

Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases (GlobeNewswire) - "Financing supports Phase 2 development of ALV-100, IND filing of ALV-200 and advancement of additional programs across the R&D pipeline. ALV-100, a bifunctional GIPR antagonist / GLP-1R agonist, designed for durable weight management with improved quality of weight loss and long-term maintenance....ALV-200, a highly selective amylin receptor 3 (AMYR3) peptide agonist, has entered IND-enabling stage. Alveus’s amylin portfolio also includes small oral molecules and multifunctional formats."

Financing • Obesity

Equipped with $160M series A, Alveus debuts into crowded obesity development landscape (FierceBiotech) - "Alveus, which launched Thursday under the stewardship of former I-Mab CEO Raj Kannan, is aiming to advance an undisclosed number of obesity candidates, with the dual-acting asset ALV-100 leading its current development roster...The biotech is dabbling in both injectable and oral administration and gave special mention to ALV-200, a highly selective amylin receptor 3 (AMYR3) peptide agonist that has now entered the IND-enabling stage."

Financing • Obesity